Role of RNA Modifications in Enhancing Mouse In Vivo Transfection Efficiency
Chemical modifications of RNA molecules play a crucial role in improving the stability, immunogenicity, and transfection efficiency of RNA therapeutics in mouse in vivo models. Unmodified RNA is highly susceptible to degradation by endogenous nucleases and can trigger innate immune responses that limit delivery success.
Common modifications include 2′-O-methylation, pseudouridine incorporation, and phosphorothioate backbone linkages. These alterations enhance resistance to serum nucleases, extend half-life in circulation, and reduce recognition by pattern recognition receptors such as Toll-like receptors (TLRs). Reduced immunogenicity prevents unwanted inflammatory responses that could interfere with gene silencing or expression.
Modified nucleotides also improve RNA folding and interaction with RNA-induced silencing complex (RISC) machinery, enhancing the potency of siRNA and microRNA mimics. In mRNA therapeutics, modifications increase translational efficiency and protein expression.
Efficient in vivo delivery systems combined with optimized RNA chemistries yield higher target gene knockdown or expression with lower doses, improving safety profiles.
Altogen Biosystems offers chemically modified RNA reagents and in vivo transfection kits optimized for mouse models, facilitating robust gene modulation in research and preclinical applications.
Understanding and utilizing RNA modifications is essential for advancing RNA-based therapeutics and functional genomics in mouse in vivo transfection studies.